Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1000 USD | -9.09% |
|
0.00% | -23.14% |
| Market Cap | 31.69M 22.48M 19.78M 18.38M 16.9M 2.17B 32.29M 219M 85.45M 1.06B 84.44M 82.64M 3.69B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 31.46M 22.32M 19.63M 18.24M 16.78M 2.16B 32.06M 218M 84.83M 1.06B 83.82M 82.04M 3.66B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -9.09% | ||
| Current month | +5.26% | ||
| 1 month | +10.99% | ||
| 3 months | +25.00% | ||
| Current year | -23.14% |
| 1 week | 0.1 | 0.11 | |
| 1 month | 0.09 | 0.11 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 2019-06-30 |
| Director of Finance/CFO | - | 2022-08-16 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 2017-12-05 |
Brad Willis
BRD | Director/Board Member | - | 2019-06-30 |
Eric Pommer
CHM | Chairman | - | 2025-04-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -9.09% | 0.00% | - | - | 23.3M | ||
| +1.97% | +2.53% | +52.73% | +156.66% | 1,037B | ||
| +1.42% | +4.96% | +54.39% | +52.34% | 615B | ||
| +1.43% | +5.25% | +37.31% | +78.74% | 448B | ||
| +5.14% | +5.84% | +37.54% | +27.28% | 326B | ||
| +1.85% | +4.64% | +38.53% | +39.87% | 293B | ||
| -0.11% | +0.97% | +22.57% | +17.81% | 264B | ||
| +0.25% | -3.10% | -24.44% | -42.25% | 216B | ||
| +1.49% | +3.68% | +21.53% | +58.21% | 198B | ||
| +0.40% | -0.64% | +18.78% | +62.28% | 162B | ||
| Average | -0.16% | +1.12% | +28.77% | +50.10% | 395.27B | |
| Weighted average by Cap. | +0.51% | +1.47% | +38.33% | +75.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.36 |
| Net income | -1.71M -1.21M -1.07M -990K -911K -117M -1.74M -11.81M -4.6M -57.33M -4.55M -4.45M -199M | -3.53M -2.51M -2.2M -2.05M -1.88M -242M -3.6M -24.45M -9.53M -119M -9.41M -9.21M -411M |
| Net Debt | -113K -79.91K -70.29K -65.31K -60.08K -7.72M -115K -779K -304K -3.78M -300K -294K -13.1M | -231K -164K -144K -134K -123K -15.8M -235K -1.6M -622K -7.74M -614K -601K -26.82M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | US$0.1000 | -9.09% | 47,000 |
| 26-07-21 | US$0.1100 | +10.00% | 39,000 |
| 26-07-20 | US$0.1000 | 0.00% | 14,000 |
| 26-07-17 | US$0.1000 | 0.00% | 6,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















